American International Group Inc. Reduces Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

American International Group Inc. trimmed its position in Hologic, Inc. (NASDAQ:HOLX) by 3.5% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 64,213 shares of the medical equipment provider’s stock after selling 2,343 shares during the period. American International Group Inc.’s holdings in Hologic were worth $4,588,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Norges Bank purchased a new position in Hologic in the fourth quarter worth about $217,529,000. Pinebridge Investments L.P. lifted its position in shares of Hologic by 39.8% during the 4th quarter. Pinebridge Investments L.P. now owns 397,251 shares of the medical equipment provider’s stock valued at $28,384,000 after buying an additional 113,050 shares in the last quarter. Louisiana State Employees Retirement System purchased a new position in shares of Hologic during the 4th quarter valued at about $1,057,000. Thematics Asset Management lifted its position in shares of Hologic by 18.0% during the 4th quarter. Thematics Asset Management now owns 433,487 shares of the medical equipment provider’s stock valued at $30,973,000 after buying an additional 66,158 shares in the last quarter. Finally, Cibc World Markets Corp lifted its position in shares of Hologic by 133.2% during the 4th quarter. Cibc World Markets Corp now owns 31,524 shares of the medical equipment provider’s stock valued at $2,252,000 after buying an additional 18,005 shares in the last quarter. 94.73% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts have recently weighed in on HOLX shares. Evercore ISI lifted their price objective on Hologic from $76.00 to $78.00 and gave the company an “in-line” rating in a research report on Thursday, April 4th. Argus boosted their price target on Hologic from $89.00 to $95.00 and gave the stock a “buy” rating in a report on Thursday, May 9th. StockNews.com raised Hologic from a “hold” rating to a “buy” rating in a report on Friday, May 3rd. JPMorgan Chase & Co. boosted their price target on Hologic from $85.00 to $91.00 and gave the stock an “overweight” rating in a report on Friday, May 3rd. Finally, Citigroup raised Hologic from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $80.00 to $95.00 in a report on Wednesday, April 3rd. Five research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $85.60.

Hologic Stock Performance

NASDAQ:HOLX opened at $73.07 on Friday. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.97 and a quick ratio of 3.29. Hologic, Inc. has a 1 year low of $64.02 and a 1 year high of $82.45. The stock’s 50 day simple moving average is $74.59 and its two-hundred day simple moving average is $74.17. The company has a market cap of $17.05 billion, a price-to-earnings ratio of 37.28, a PEG ratio of 2.40 and a beta of 1.00.

Hologic (NASDAQ:HOLX) last released its earnings results on Thursday, May 2nd. The medical equipment provider reported $1.03 earnings per share for the quarter, beating the consensus estimate of $0.98 by $0.05. The firm had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1 billion. Hologic had a return on equity of 18.91% and a net margin of 11.78%. The company’s revenue for the quarter was down .8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.06 EPS. As a group, equities analysts anticipate that Hologic, Inc. will post 4.08 earnings per share for the current fiscal year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.